These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 11089613)

  • 1. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy.
    Bart PA; Rizzardi GP; Tambussi G; Chave JP; Chapuis AG; Graziosi C; Corpataux JM; Halkic N; Meuwly JY; Munoz M; Meylan P; Spreen W; McDade H; Yerly S; Perrin L; Lazzarin A; Pantaleo G
    AIDS; 2000 Sep; 14(13):1887-97. PubMed ID: 10997391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
    Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
    JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP; De Boer RJ; Hoover S; Tambussi G; Chapuis A; Halkic N; Bart PA; Miller V; Staszewski S; Notermans DW; Perrin L; Fox CH; Lange JM; Lazzarin A; Pantaleo G
    J Clin Invest; 2000 Mar; 105(6):777-82. PubMed ID: 10727446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S; Descamps D; Boué F; Livrozet JM; Lafeuillade A; Aquilina C; Troisvallets D; Goetschel A; Brun-Vezinet F; Mamet JP; Thiaux C;
    Antivir Ther; 2003 Apr; 8(2):163-71. PubMed ID: 12741629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
    Hengge UR; Goos M; Esser S; Exner V; Dötterer H; Wiehler H; Borchard C; Müller K; Beckmann A; Eppner MT; Berger A; Fiedler M
    AIDS; 1998 Dec; 12(17):F225-34. PubMed ID: 9863864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
    McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
    Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H;
    AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
    Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G;
    AIDS; 2002 Mar; 16(4):589-96. PubMed ID: 11873002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland.
    Nadal D; Steiner F; Cheseaux JJ; Lazarevitch CA; Aebi C; Kind C; Rudin C
    Infection; 2000 Sep; 28(5):287-96. PubMed ID: 11073135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virological efficacy and plasma drug concentrations of nelfinavir plus saquinavir as salvage therapy in HIV-infected patients refractory to standard triple therapy.
    Reiser M; Salzberger B; Stiepel A; Hoetelmans R; Diehl V; Fätkenheuer G
    Eur J Med Res; 1999 Feb; 4(2):54-8. PubMed ID: 10066640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy.
    Andreoni M; Parisi SG; Sarmati L; Nicastri E; Ercoli L; Mancino G; Sotgiu G; Mannazzu M; Trevenzoli M; Tridente G; Concia E; Aceti A
    AIDS; 2000 Jan; 14(1):23-9. PubMed ID: 10714564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
    JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
    Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips AN; Johnson MA
    AIDS; 2000 Jul; 14(11):1545-52. PubMed ID: 10983641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.